MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

Search

Lyell Immunopharma Inc

Chiusa

0.43

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.42

Massimo

0.47

Metriche Chiave

By Trading Economics

Entrata

-147M

-192M

Vendite

-23K

11K

EPS

-0.172

Margine di Profitto

-1,744,863.636

Dipendenti

300

EBITDA

-12M

-58M

Raccomandazioni

By TipRanks

Raccomandazioni

Vendi

Previsioni per 12 mesi

+132.56% upside

Dividendi

By Dow Jones

Utili prossimi

5 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-85M

131M

Apertura precedente

0.43

Chiusura precedente

0.43

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Lyell Immunopharma Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 apr 2025, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Nomura to Buy Macquarie's U.S., European Public Asset Management Business

21 apr 2025, 22:37 UTC

Acquisizioni, Fusioni, Takeovers

Hino Motors, Mitsubishi Fuso Moving Toward Merger, Nikkei Says

21 apr 2025, 23:58 UTC

Discorsi di Mercato

Transurban on Bumpy Road During NSW Toll Review -- Market Talk

21 apr 2025, 23:46 UTC

Discorsi di Mercato

Gold Rises Amid Likely Safe-Haven Demand -- Market Talk

21 apr 2025, 23:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

21 apr 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Decline as Uncertainty Over U.S. Trade Policy Continues -- Market Talk

21 apr 2025, 23:22 UTC

Acquisizioni, Fusioni, Takeovers

Nomura to Pay $1.8B for Macquarie's U.S. and European Public Asset-Management Business

21 apr 2025, 23:22 UTC

Acquisizioni, Fusioni, Takeovers

Nomura to Acquire Macquarie's U.S. and European Public Asset-Management Business

21 apr 2025, 22:35 UTC

Notizie principali

Harvard Is Suing the Trump Administration -- 2nd Update

21 apr 2025, 22:02 UTC

Notizie principali

Harvard Is Suing the Trump Administration -- Update

21 apr 2025, 21:46 UTC

Notizie principali

Fed, Tariff Fears Send Dow Down More than 900 Points -- Update

21 apr 2025, 21:03 UTC

Notizie principali

Harvard Is Suing the Trump Administration -- WSJ

21 apr 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

21 apr 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

21 apr 2025, 20:28 UTC

Notizie principali

Fed, Tariff Fears Send Dow Down More than 900 Points -- WSJ

21 apr 2025, 20:24 UTC

Notizie principali

Dow and Dollar Drop on Jitters Over Fed and TradeHeadline -- WSJ

21 apr 2025, 19:14 UTC

Discorsi di Mercato

Oil Futures Give Back Pre-Holiday Gains -- Market Talk

21 apr 2025, 19:11 UTC

Discorsi di Mercato

U.S. Natural Gas Falls as China Turns Elsewhere for LNG -- Market Talk

21 apr 2025, 19:07 UTC

Notizie principali

Uber Faces FTC Lawsuit Alleging Deceptive Billing, Cancellation Practices -- Update

21 apr 2025, 18:44 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

21 apr 2025, 18:44 UTC

Discorsi di Mercato

Trump Seen as Unlikely to Fire Powell Despite Market Jitters -- Market Talk

21 apr 2025, 18:28 UTC

Discorsi di Mercato

Gold Finishes at New Record as Equities Slide -- Market Talk

21 apr 2025, 18:26 UTC

Notizie principali

Dow Industrials, Dollar Fall on Fed and Trade Concerns -- WSJ

21 apr 2025, 16:27 UTC

Discorsi di Mercato

Weaker Dollar No Longer Supporting Commodities Due to Fed Fears -- Market Talk

21 apr 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

21 apr 2025, 16:16 UTC

Notizie principali

Dow and Dollar Drop on Jitters Over Fed and Trade -- WSJ

21 apr 2025, 16:00 UTC

Discorsi di Mercato

Crocs Could Double Some Prices as Tariffs Threaten Heydude Line -- Market Talk

21 apr 2025, 15:53 UTC

Utili

Canadian Telcos Need to Show Pricing Discipline as Subscriber Growth Faces Challenges -- Analysis

21 apr 2025, 15:51 UTC

Discorsi di Mercato

Stock Market Losses Keep Pressure On Oil Prices -- Market Talk

21 apr 2025, 15:49 UTC

Discorsi di Mercato

Capital Plans, M&A in Focus When Precious Metals Miners Report -- Market Talk

Confronto tra pari

Modifica del prezzo

Lyell Immunopharma Inc Previsione

Obiettivo di Prezzo

By TipRanks

132.56% in crescita

Previsioni per 12 mesi

Media 1 USD  132.56%

Alto 1 USD

Basso 1 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lyell Immunopharma Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Vendi

2 ratings

0

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

0.429 / 0.4385Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.